The Metabolism of Gold: Possible Mechanisms for Perturbations of Copper and Zinc Homeostasis

  • C. Frank ShawIII
Part of the Experimental Biology and Medicine book series (EBAM, volume 2)


The use of gold complexes - chrysotherapy - for treating rheumatoid arthritis is well established and can actually alter the course of the disease, unlike most anti-inflammatory drugs which do not stop the underlying tissue damage (1). Although many theories of action have been proposed (1), none can be considered to be well established and space does not permit a detailed evaluation of them. However, one possibility, which is not exclusive of other postulated mechanisms, is that gold may affect copper and zinc homeostasis. Indeed these essential metals - as well as penicillamine which chelates both of them - have been used to treat arthritis.


Rheumatoid Arthritis Lysyl Oxidase Gold Compound Zinc Homeostasis Birth Control Pill 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    C. F. Shaw III, Inorg. Persp. Med. Biol., 2, 287–355 (1979).Google Scholar
  2. 2.
    M. H. Weisman and D. Hannifin, Arthritis Rheum., 22 922–925 (1980).CrossRefGoogle Scholar
  3. 3.
    D. T. Hill, B. M. Sutton, P. J. Sadler, G. H. M. Kalis, and J. M. Trooster, 179th Meeting of the ACS, Houston, IX, 1980, Abstract MED 1–16.Google Scholar
  4. 4.
    M. Mazid, M. Razi, P. J. Sadler, G. N. Greaves, S. Gurman, M. Koch and J. Phillips, Chem. Commun., 1261 (1980).Google Scholar
  5. 5.
    A. A. Isab and P. J. Sadler, Chem. Commun., 1051–2 (1976).Google Scholar
  6. 6.
    C. F. Shaw III, J. Eldridge, M. P. Cancro, J. Inorg. Biochem., 14, 267–274 (1981).CrossRefGoogle Scholar
  7. 7.
    C. F. Shaw, J. Eldrige and M. P. Cancro, unpublished results.Google Scholar
  8. 8.
    D. T. Hill and B. M. Sutton, Crystal Structure Commun., 9, 679 (1980).Google Scholar
  9. 9.
    J. Laib and C. F. Shaw, unpublished studies.Google Scholar
  10. 10.
    C. F. Shaw III, G. Schmidtz, H. O. Thompson and P. Witkiewicz, J. Inorg. Biochem., 10, 317–330 (1979).PubMedCrossRefGoogle Scholar
  11. 11.
    C. J. Danpure, Biochem. Soc. Trans., 4, 536–544 (1977).Google Scholar
  12. 12.
    R. W. Mason, Pharmacology, 15, 536–547 (1977).PubMedCrossRefGoogle Scholar
  13. 13.
    D. A. Campion, R. Olsen, A. Bohan, and R. Bluestone, J. Rheumatol. Suppl., 1, 112 (1974).Google Scholar
  14. 14.
    R. B. Simpson, J. Am. Chem. Soc., 83, 4711–4717 (1961).CrossRefGoogle Scholar
  15. 15.
    H. O. Thompson, J. Blaszak, C. J. Knudtson, and C. F. Shaw III, Bioinorg. Chem., 9, 375–388 (1978).CrossRefGoogle Scholar
  16. 16.
    G. Schmitz, D. T, Minkel, D. Gingrich, and C. F. Shaw III, J. Inorg. Biochem., 12, 293–306 (1980).PubMedCrossRefGoogle Scholar
  17. 17.
    E. M. Mogilnicka and J. K. Piotrowski, Biochem. Pharmacol., 28, 2625–2631 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    E. M. Mogilnicka and M. Webb, J. Appl. Toxicol., 1, 42–49 (1981).PubMedCrossRefGoogle Scholar
  19. 19.
    C. F. Shaw, H. O. Thompson, P. Witkiewicz and R. W. Satre, Toxicol. Appl. Pharm., in press.Google Scholar
  20. 20.
    M. W. Whitehouse and W. R. Walker, Agents Action, 8 85–90 (1978).CrossRefGoogle Scholar
  21. 21.
    C.F. Shaw III, “Trace Elements in the Pathogenesis and Treatment of Inflammatory Conditions,” K. Rainsford, K. Brune and M.W. Whitehouse, Eds., Birkhäuser-Verlag, Basel, 1980, pp. 509–528.Google Scholar

Copyright information

© The Humana Press Inc. 1982

Authors and Affiliations

  • C. Frank ShawIII
    • 1
  1. 1.Department of ChemistryThe University of Wisconsin-MilwaukeeMilwaukeeUSA

Personalised recommendations